Coloplast A/S Stock Forecast, Price & News

+0.08 (+0.51 %)
(As of 06/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume23,631 shs
Average Volume100,134 shs
Market Capitalization$34.02 billion
P/E Ratio56.25
Dividend Yield1.47%
30 days | 90 days | 365 days | Advanced Chart
Receive CLPBY News and Ratings via Email

Sign-up to receive the latest news and ratings for Coloplast A/S and its competitors with MarketBeat's FREE daily newsletter.

Coloplast A/S logo

About Coloplast A/S

Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catheterization for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.02 out of 5 stars

Medical Sector

1092nd out of 2,105 stocks

Surgical Appliances & Supplies Industry

24th out of 40 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Coloplast A/S (OTCMKTS:CLPBY) Frequently Asked Questions

Is Coloplast A/S a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coloplast A/S in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Coloplast A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLPBY, but not buy additional shares or sell existing shares.
View analyst ratings for Coloplast A/S
or view top-rated stocks.

What stocks does MarketBeat like better than Coloplast A/S?

Wall Street analysts have given Coloplast A/S a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Coloplast A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Coloplast A/S's earnings last quarter?

Coloplast A/S (OTCMKTS:CLPBY) announced its quarterly earnings results on Thursday, May, 2nd. The company reported $0.07 EPS for the quarter, meeting the Zacks' consensus estimate of $0.07. The business earned $688.45 million during the quarter. Coloplast A/S had a net margin of 21.62% and a trailing twelve-month return on equity of 69.30%.
View Coloplast A/S's earnings history

How has Coloplast A/S's stock been impacted by COVID-19 (Coronavirus)?

Coloplast A/S's stock was trading at $13.5590 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CLPBY stock has increased by 16.2% and is now trading at $15.75.
View which stocks have been most impacted by COVID-19

How often does Coloplast A/S pay dividends? What is the dividend yield for Coloplast A/S?

Coloplast A/S announced a dividend on Friday, May 14th. Stockholders of record on Monday, May 17th will be paid a dividend of $0.3652 per share on Monday, May 24th. This represents a yield of 2.34%. The ex-dividend date of this dividend is Friday, May 14th. This is a positive change from Coloplast A/S's previous dividend of $0.28.
View Coloplast A/S's dividend history

Is Coloplast A/S a good dividend stock?

Coloplast A/S pays an annual dividend of $0.22 per share and currently has a dividend yield of 1.47%. The dividend payout ratio of Coloplast A/S is 73.33%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Coloplast A/S will have a dividend payout ratio of 61.11% next year. This indicates that Coloplast A/S will be able to sustain or increase its dividend.
View Coloplast A/S's dividend history.

Who are Coloplast A/S's key executives?

Coloplast A/S's management team includes the following people:
  • Mr. Kristian Villumsen, Pres & CEO (Age 51, Pay $2.38M)
  • Mr. Anders Lonning-Skovgaard, Exec. VP & CFO (Age 49, Pay $1.19M)
  • Mr. Allan Rasmussen, Exec. VP of Global Operations (Age 54, Pay $1.08M)
  • Mr. Paul Marcun, Exec. VP of Growth (Age 55, Pay $1.94M)
  • Mr. Thomas Barfod, Sr. Controller & Director (Age 51, Pay $72.23k)
  • Ellen Bjurgert, VP of Investor Relations
  • Dennis Kaysen, Director of Corp. Communications
  • Ms. Camilla G. Mohl, Sr. VP of People & Culture
  • Mr. Nicolai Buhl Andersen, Exec. VP of Innovation
  • Mr. Alain Morvan, Sr. VP of Sales Europe

Who are some of Coloplast A/S's key competitors?

What is Coloplast A/S's stock symbol?

Coloplast A/S trades on the OTCMKTS under the ticker symbol "CLPBY."

How do I buy shares of Coloplast A/S?

Shares of CLPBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coloplast A/S's stock price today?

One share of CLPBY stock can currently be purchased for approximately $15.75.

How much money does Coloplast A/S make?

Coloplast A/S has a market capitalization of $34.02 billion and generates $2.76 billion in revenue each year. The company earns $585.21 million in net income (profit) each year or $0.30 on an earnings per share basis.

How many employees does Coloplast A/S have?

Coloplast A/S employs 12,500 workers across the globe.

When was Coloplast A/S founded?

Coloplast A/S was founded in 1954.

What is Coloplast A/S's official website?

The official website for Coloplast A/S is www.coloplast.com.

Where are Coloplast A/S's headquarters?

Coloplast A/S is headquartered at HOLTEDAM 1-3, HUMLEBAEK G7, 3050.

How can I contact Coloplast A/S?

Coloplast A/S's mailing address is HOLTEDAM 1-3, HUMLEBAEK G7, 3050. The company can be reached via phone at (454) 911-1111 or via email at [email protected]

This page was last updated on 6/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.